Schmallenberg Virus Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Animal Type, By Region & Competition, 2021-2031F

The Global Schmallenberg Virus Treatment Market is projected to expand from USD 147.67 Million in 2025 to USD 234.85 Million by 2031, registering a CAGR of 8.04%. This market sector comprises veterinary interventions, including preventive vaccinations, diagnostic instruments, and supportive care therapies aimed at reducing the Orthobunyavirus's detrimental effects on ruminant livestock. Growth is primarily propelled by the critical necessity to avert severe financial setbacks caused by congenital defects and stillbirths within cattle and sheep populations. Furthermore, the rising emphasis on animal welfare and the requirement for comprehensive herd health strategies in endemic areas continue to drive the demand for efficient control measures.

High-impact losses underscore the urgency of this market; the National Sheep Association noted in 2024 that early lambing flocks in hard-hit regions suffered lamb losses ranging from 10% to 25%, emphasizing the need for dependable management solutions. Despite this strong demand, market growth faces a significant hurdle due to the sporadic and cyclical nature of viral outbreaks. This unpredictability creates unstable revenue streams and complicates long-term production planning for pharmaceutical developers, often discouraging sustained investment in the creation of new therapeutic options.

Market Driver

The rising frequency of Schmallenberg virus outbreaks in livestock serves as a major engine for market expansion, generating an immediate need for diagnostic and management resources. As the virus returns in cyclical waves, the sudden spike in congenital malformations and stillbirths requires prompt veterinary action to limit transmission and maintain herd health. According to an Agriland report from February 2025, the number of confirmed cases in Ireland surged by 2,200% in 2024 compared to the previous year. This sharp increase highlights the disease's volatility and the vital importance of having treatment options readily available during infection peaks, while the pathogen's impact on various ruminants is evidenced by the Irish Farmers Journal reporting 12 cattle herds testing positive in 2025.

Moreover, the economic necessity of minimizing production losses pushes producers to fund effective treatment and supportive care measures. The costs associated with difficult births, veterinary services, and the loss of marketable offspring compel farm managers to implement strict health protocols to safeguard their profits. A study published in the Veterinary Record in August 2025, focusing on the 2023-2024 UK lambing season, revealed that 44 farms with confirmed infections faced considerably greater negative impacts on financial stability and flock welfare than unaffected farms. These financial strains necessitate the use of thorough surveillance and response strategies, as reducing the damage to farm profitability is crucial for maintaining ruminant production systems in affected regions.

Market Challenge

The expansion of the Global Schmallenberg Virus Treatment Market is significantly hindered by the sporadic and cyclical pattern of outbreaks. Unlike diseases that demand regular, annual treatments, this Orthobunyavirus demonstrates a volatile transmission rate influenced by vector activity and herd immunity, resulting in phases of intense demand followed by long periods of market inactivity. This unpredictability makes it extremely difficult for pharmaceutical manufacturers to predict revenue or rationalize the heavy capital investment needed for researching and producing new therapeutics.

As a result, stakeholders encounter major risks regarding inventory control, frequently facing stock shortages during spikes or product wastage during quiet periods. This instability is highlighted by the National Farmers Union, which reported a sudden viral resurgence in the UK livestock sector in early 2024, with 63 confirmed cases occurring over just six weeks, indicative of the typical three-to-five-year outbreak cycle. Such erratic fluctuations discourage long-term commitment to developing advanced medical solutions, as companies tend to favor stable markets over those characterized by boom-and-bust cycles.

Market Trends

There is a growing trend toward adopting rapid point-of-care diagnostic kits as livestock producers look to avoid the logistical delays inherent in centralized reference laboratories. Without immediate on-site confirmation, farmers deal with uncertainty during sporadic outbreaks, which impedes the quick isolation of infected animals and complicates herd management. The strain on existing testing facilities highlights this issue; as noted by Agriland in February 2025, the Department of Agriculture, Food and the Marine (DAFM) had to analyze 369 cattle and 84 sheep samples to confirm the virus's presence during the 2024 surveillance period. This heavy reliance on off-site testing is driving the market toward field-ready tools capable of real-time pathogen detection, thereby shortening the time between suspicion and action.

Concurrently, the development of multivalent and combination vaccines is being fast-tracked due to the overlapping geographic presence of the Schmallenberg virus and other midge-borne diseases like Bluetongue. Pharmaceutical developers are increasingly prioritizing broad-spectrum formulations to offer dual protection, effectively lowering the labor and costs involved in administering separate vaccines to ruminant herds. The market's need for such integrated solutions is emphasized by the magnitude of simultaneous viral threats; according to a Teagasc update in January 2025, the Netherlands reported over 10,000 Bluetongue-positive locations in 2024, presenting a strong argument for combined prophylactic strategies to tackle the shared vector challenge across European regions.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis
• MSD Animal Health
• Elanco Animal Health
• Neogen Corporation
• Heska Corporation
• Phibro Animal Health
• IDT Biologika
• Phibro Animal Health
• Dechra Pharmaceuticals

Report Scope

In this report, the Global Schmallenberg Virus Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Schmallenberg Virus Treatment Market, By Treatment Type

• Supportive Care
• Vector Control
• Preventive Measures

Schmallenberg Virus Treatment Market, By Animal Type

• Cattle
• Sheep
• Goats

Schmallenberg Virus Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Schmallenberg Virus Treatment Market.

Available Customizations:

Global Schmallenberg Virus Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).